GlassScriptPhysician profile
Li Lisa Ge
NPI 1194709188
$19,163.70
in general payments reported to CMS, 2019-2025
42 companies · $4,616 in 2025
The $4,616 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $1,093 · 2022: $8,826 · 2023: $2,019 · 2024: $2,464 · 2025: $4,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,520 · Consulting Fee: $1,300 · Long Term Medical Supply Or Device Loan: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,519.95 |
| Consulting Fee | $1,300.00 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,517.07 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $2,024.55 | 2019-2025 | |
| Pfizer INC. | $1,830.91 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,291.05 | 2021-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $1,214.80 | 2021-2025 | Enhertu, Lynparza, Movantik |
| Eisai INC. | $659.06 | 2021-2025 | |
| Lilly USA, LLC | $640.16 | 2021-2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $472.89 | 2023-2025 | Phesgo, Itovebi, Perjeta |
| Tersera Therapeutics LLC | $310.93 | 2023-2025 | Zoladex, Quzyttir |
| Puma Biotechnology, INC. | $265.43 | 2023-2025 | Nerlynx |
| Myriad Genetic Laboratories, INC. | $239.90 | 2022-2024 | Mychoice Cdx, Myrisk, Bracanalysis Cdx |
| Seagen INC. | $224.06 | 2021-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $129.56 | 2021-2025 | Keytruda, Lynparza |
| Blueprint Medicines Corporation | $121.84 | 2021 | |
| Glaxosmithkline, LLC. | $109.74 | 2021-2023 | Zejula |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Ge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.